Dr Ali Alloueche
Vice President, Global Head Business Development, Alliance Management, and External R&D at the Hilleman Laboratories
Dr. Alloueche joined Hilleman Laboratories (HL) on 1st October 2020, and oversees HL’s Business Development, Alliance Management and External R&D and is currently based at the Wellcome Trust Office in London, UK.
Prior to joining Hilleman, Dr. Alloueche worked at Takeda Vaccines, Switzerland where he spent 6.5 years as Head of Technology Strategy and Alliance Management, with global responsibility for external R&D, pipeline development and partnerships management with public and private stakeholders and national governments. Dr. Alloueche has also worked at Novartis, GSK and AFFiRiS in many roles with increasing responsibilities in R&D, Business Development, Alliance Management, Strategic Planning and Corporate Development. During this time, he led and contributed to the development, licensure, and commercialisation of over 15 vaccines for infectious and non-infectious diseases including in India. He completed several successful in-licensing, out-licensing and spin-out transactions with biotech and large pharma companies, venture capitalists, national governments and NGOs across the entire vaccine development and commercialisation chain.
Dr. Alloueche spent 12 years in academic research in the UK and his work contributed to several malaria vaccines and drugs development and implementation in Africa and Asia. This gave him a unique opportunity to learn and appreciate the importance of vaccines as an effective and equitable global healthcare tool. Dr Alloueche authored and co-authored several publications in prestigious journals like The Lancet and Nature Medicine. Dr. Alloueche holds a PhD in Molecular Biology from the University of Glasgow and was represented Takeda as a founding member of CEPI and served on Scientific Advisory Committee until January 2021.